US 12,129,293 B2
Medical device for administering anti-IL-23 antibodies
Jacqueline Benson, San Francisco, CA (US); Jill Carton, Collegeville, PA (US); Mark Cunningham, Kennett Square, PA (US); Yevgeniya Orlovsky, Chadds Ford, PA (US); Robert Rauchenberger, Martinsried (DE); and Raymond Sweet, Bryn Mawr, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Feb. 22, 2021, as Appl. No. 17/181,778.
Application 17/181,778 is a division of application No. 16/013,141, filed on Jun. 20, 2018, granted, now 10,954,297.
Application 16/013,141 is a division of application No. 15/694,107, filed on Sep. 1, 2017, granted, now 10,030,070, issued on Jul. 24, 2018.
Application 15/694,107 is a division of application No. 15/142,765, filed on Apr. 29, 2016, granted, now 9,783,607, issued on Oct. 10, 2017.
Application 15/142,765 is a division of application No. 13/524,122, filed on Jun. 15, 2012, granted, now 9,353,181, issued on May 31, 2016.
Application 13/524,122 is a division of application No. 12/855,354, filed on Aug. 12, 2010, granted, now 7,993,645, issued on Aug. 9, 2011.
Application 12/855,354 is a division of application No. 11/617,503, filed on Dec. 28, 2006, granted, now 7,935,344, issued on May 3, 2011.
Claims priority of provisional application 60/754,889, filed on Dec. 29, 2005.
Prior Publication US 2021/0188966 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/26 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 39/3955 (2013.01); A61K 47/26 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01)] 13 Claims
 
1. A medical device containing a liquid pharmaceutical formulation of an isolated IL-23p19 antibody, comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:
a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50;
a CDRL2 amino acid sequence of SEQ ID NO:56; and
a CDRL3 amino acid sequence of SEQ ID NO:73, said heavy chain variable region comprising:
a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:5;
a CDRH2 amino acid sequence of SEQ ID NO:20; and
a CDRH3 amino acid sequence of SEQ ID NO:44, wherein said device is suitable for contacting or administering said IL-23p19 antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.